Premium
[P1–240]: CLINICAL IMPACT OF CEREBROSPINAL FLUID BIOMARKERS IN MILD COGNITIVE IMPAIRMENT DIAGNOSIS
Author(s) -
Cognat Emmanuel,
Troussière AnneCécile,
Wallon David,
Dumurgier Julien,
Magnin Eloi,
Duron Emmanuelle,
Gabelle Audrey,
Pasquier Florence,
Hannequin Didier,
Robert Philippe,
Hugon Jacques,
MoutonLiger François,
Paquet Claire
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.060
Subject(s) - medicine , lumbar puncture , cerebrospinal fluid , cognitive impairment , prospective cohort study , cohort , clinical trial , disease
TDP had lower levels of sAPPb and higher levels of YKL-40 in CSF compared to controls (Fig. 1). The sAPPb/YKL-40 ratio was lower in both FTLD groups compared to controls. In the ROC analysis (Fig. 2), the sAPPb/YKL-40 ratio had an area under the curve of 0.91 (95%CI 0.86-0.96) to distinguish FTLD subjects from controls, but lower values to distinguish FTLD from AD (AUC 0.70; 95%CI 0.61-0.79) and to discriminate FTLDTau from FTLD-TDP (AUC 0.67; 95%CI 0.51-0.82). Conclusions:These findings suggest that the sAPPb/YKL-40 ratio could be of interest to distinguish patients with FTLD from those with similar clinical phenotypes. Although the ratio cannot be used to discriminate between the main pathologies underlying FTLD, it might be useful to interrogate the neuropathological substrate in some clinical scenarios and, eventually, to select potential candidates for clinical trials.